{"count": 1, "results": [{"_id": "34874833", "pmid": 34874833, "title": "Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.", "journal": "Clin Exp Rheumatol", "authors": ["Sun F", "Zhang D", "Wang H", "Wang H", "Liu Z", "Geng S", "Wang X", "Li T", "Wan W", "Lu L", "Teng X", "Morel L", "Ye S"], "date": "2022-09-01T00:00:00Z", "doi": "10.55563/clinexprheumatol/7y5ku8", "meta_date_publication": "2022 Sep", "meta_volume": "40", "meta_issue": "9", "meta_pages": "1733-1737", "score": 50248.24, "text_hl": "For 164 @SPECIES_9606 @@@patients@@@ who did not meet the @VARIANT_tmVar:c|SUB|T|2|T;HGVS:c.2T>T;VariantGroup:0 @@@T2T@@@ criteria at entry, 59.0% and 43.6% of the 78 @SPECIES_9606 @@@patients@@@ taking @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in this population attained the @<m>DISEASE_Oculocerebrorenal_Syndrome</m> @DISEASE_MESH:D009800 @@@lupus low disease@@@ activity status (LLDAS) and remission endpoints at last visit, respectively, as compared to 37.2% and 24.4% of the 86 @SPECIES_9606 @@@patients@@@ in the placebo/nil group (LLDAS p=0.008; remission p=0.013). ", "citations": {"NLM": "Sun F, Zhang D, Wang H, Wang H, Liu Z, Geng S, Wang X, Li T, Wan W, Lu L, Teng X, Morel L, Ye S. Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis. Clin Exp Rheumatol. 2022 Sep;40(9):1733-1737. PMID: 34874833", "BibTeX": "@article{34874833, title={Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.}, author={Sun F and Zhang D and Wang H and Wang H and Liu Z and Geng S and Wang X and Li T and Wan W and Lu L and Teng X and Morel L and Ye S}, journal={Clin Exp Rheumatol}, volume={40}, number={9}, pages={1733-1737}}"}}]}